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Edited by Giulio Superti-FurgaAbstract Systems biology promises to impact signiﬁcantly on
the drug discovery process. One of its ultimate goals is to provide
an understanding of the complete set of molecular mechanisms
describing an organism. Although this goal is a long way oﬀ,
many useful insights can already come from currently available
information and technology. One of the biggest challenges in
drug discovery today is the high attrition rate: many promising
candidates prove ineﬀective or toxic owing to a poor understand-
ing of the molecular mechanisms of biological systems they tar-
get. A ‘‘systems’’ approach can help identify pathways related to
a disease and can suggest secondary eﬀects of drugs that might
cause these problems and thus ultimately improve the drug dis-
covery pipeline.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Since the dawn of medicine, ‘‘systems’’ approaches were
used to identify eﬀective treatments. One of the most complex
biological systems – a patient with a disease – was eﬀectively
treated as a black-box, and exposed to all manner of herbal
mixtures and religious rituals. Those treatments showing ben-
eﬁcial eﬀects would be given again to others with similar symp-
toms, and would eventually become established as drugs. And
for thousands of years this process was largely unchanged.
The last ﬁfty years saw the advent of molecular biology and
with it modern drug discovery. The observation that drugs
arising from herbal remedies typically acted by binding to a
single receptor molecule changed the discovery process. To de-
sign a drug, one now normally searches for a magic bullet that
binds speciﬁcally to a rationally chosen target. This reduction-
ist approach has since proved highly eﬀective, and drugs de-
signed in this way have been available for decades. However,
it has certain drawbacks. Probably the biggest is that the pos-
sibility of a designed molecule binding in places other than the
target is often neglected until comparatively late in the discov-
ery process, where many candidate drugs fail. This can, how-
ever, have some fortuitous consequences whereby a drug
designed for one purpose does something unpredicted, but
nevertheless beneﬁcial (e.g., Gleevec [1]).*Corresponding author. Fax: +49 6221 387 517.
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light the need to consider the entire system when designing
drugs. Fortunately, we are now witnessing breakthroughs in
systems biology [2] driven by the latest high-throughput exper-
imental and computational methods. The result is a much bet-
ter understanding of whole systems, and with it the emergence
of possibilities to augment the drug discovery process [3–5].
Here, we discuss a few ways in which systems approaches
can already make a diﬀerence. Our particular focus is on the
use of pathways as a central reference to provide a more holis-
tic view of biological processes relevant to drug discovery.2. Pathways and pathway resources
The cell can be considered to be a complex network of inter-
acting molecules. Despite many decades of experiments and
many thousands of data points, this network is still very far
from being complete. Because of its complexity biologists have
preferred to consider parts of the cell network, hence the no-
tion of pathways, or sets of molecules acting in concert, usu-
ally involved in a particular function or process, to the extent
that it is convenient to consider them in isolation.
Academic pathway and interaction initiatives focus largely
on developing fundamental computational tools to integrate
and visualise data from a variety of sources (e.g. [6–8]). Most
information comes from high-throughput protein–protein
interaction discovery methods (e.g. [9–13]), and as a result
tends to be biased towards non-human model organisms:
i.e., Yeast, Fly & Worm. For these, there is a growing body
of knowledge that is gradually providing a more holistic pic-
ture of the organism.
Other initiatives focus on gathering textbook like knowl-
edge using experts and consultation with the literature. There
are now over 150 biological pathway databases, with diﬀerent
emphasis and coverage [http://cbio.mskcc.org/prl]. Among the
best known are the signaling pathway collections of Biocarta
(http://cgap.nci.nih.gov/Pathways/) or STKE (http://stke.
sciencmag.org), and metabolic pathways in KEGG (http://
www.genome.jp/keg/kegg2.html) [14]. More recently, ambi-
tious projects like Reactome (http://www.reactome.org) have
begun to represent pathways as a system of reactions to allow
the consideration of variables like time and concentration.
These resources, while extremely useful, have several draw-
backs. A major one is incomplete coverage: many parts of
the cell network have yet to be studied in suﬃcient detail,blished by Elsevier B.V. All rights reserved.
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For example, Biocarta contains over 300 pathways in human,
but these involve only about 1500 genes from a genome with
well over 20000. The missing links can, in principle, be added
by considering the results from coarser interactions studies like
the two-hybrid or TAP systems, but here one necessarily intro-
duces many new problems, as these data are highly error prone
[15,16]. There are also problems related to inconsistencies
caused by idiosyncrasies of authors, and of incompatibilities
in data formats. Further annotation and experiments to test
poorly understood details will gradually remove inconsisten-
cies, and new standards like the Systems Biology Markup Lan-
guage (SBML) [17] promise for better compatibility. However,
it will likely be decades before a complete set of pathways is
available.3. Pathways in drug discovery
Pathway collections have many uses in drug discovery and
are already considered by the industry. Here one needs to be
pragmatic: questions asked during drug discovery need an-
swers quickly, and methods that provide the most reliable
answers given the currently available data are paramount.
Pathways can serve as a framework for generating hypothe-
sis for further discoveries, and as such are already useful for
many stages of the drug discovery pipeline from identifying
novel drug targets to assessing toxicological eﬀects. Path-
ways put a drug target into context: one can chart those
in which a target is seen, and thus make educated guesses
about the eﬀects that blocking the target are likely to have.
Proteins that are highly connected in interaction networks
are much more likely to be lethal when deleted [18] than
others, which calls into question the wisdom targeting them
to achieve subtle eﬀects; though they may be ideal targets
for harsher therapies (e.g., for Cancer) where one wishes
to kill over active cells (e.g., the drug glendanamycin, which
targets the interaction hub HSP90 [19,20]). One can also
look at where proteins similar (i.e., homologous) to the tar-
get lie, and make inferences about secondary eﬀects of a
drug with imperfect speciﬁcity.
Academic resources are not tailored for drug discovery, and
this has inspired several commercial providers focusing on
pathways relevant to human disease. For instance companies
such as Ingenuity Systems, Genego, Ariadne Genomics pro-
vide human pathways together with information on various
drug action, and concentrate on using pathways for analysis
of experimental genomic and proteomic data highly relevant
in target discovery and validation. Other providers oﬀer lists
of pathway elements for representing pathways in scientiﬁc
publications (e.g., Protein Launch) with a focus on graphical
display. Cambridge Cell Networks (CCNet) concentrates on
pathways in pre-clinical drug safety and toxicology. Even
though the biological systems are not fully understood, these
providers, as well as eﬀorts within large pharmaceutical com-
panies, are beginning to generate useful pathway atlases for
studying disease physiology.
For obvious reasons, commercial eﬀorts also place a greater
emphasis on integrating chemical data into pathways. This can
also be powerful as one can map known drugs or chemical
modulators onto pathway collections and exploit chemoinfor-matics tools, for instance to see where compounds similar to a
candidate are known to act within the system.4. Practical applications: helping to answer questions in drug
discovery
Below we pose a number of questions that are typical of
the drug discovery process and illustrate how the pathway
framework can provide some answers, or suggest further
experiments.
4.1. Is a drug target promising?
Target discovery and validation are early, but critical parts of
drug discovery. Pathways can be a great aid to testing the valid-
ity of a target. At the very simplest level, they can reveal how a
target normally behaves – its interconnections in the cell: pro-
teins upstream or downstream of it in signaling cascades or
metabolic pathways, etc. One can see the possible knock-on ef-
fect of interfering with a target: the downstream eﬀects may be
beneﬁcial in one system and detrimental in another. This
knowledge can be a great aid when deciding whether a target
is worth pursuing: targeting a protein with too many connec-
tions might prove disastrous and prompt the search for an
alternative. For instance, it may be worth choosing a kinase
further downstream to avoid a compound having detrimental
eﬀects owing to its action in many pathways.
In many instances, however, drug targets are newly dis-
covered and thus their full biological role is not known. This
necessitates constant updates of the connectivity of a target
throughout the lifecycle of a drug discovery project. An
interesting example of this is cyclooxygenase-2 (Cox-2), ﬁrst
puriﬁed in 1976 and cloned in 1988 [21–24]. Its biochemical
pathway, represented as its role in prostanoid formation
from the metabolism of arachidonic acid (Fig. 1) [25],
undoubtedly sparked many drug discovery programmes in
the late 1980s and early 1990s. This rather simple pathway
diﬀers markedly from its term connectivity when mapped
using the current literature (Medline; Fig. 1) and represents
the challenges of the necessary reductionism of a drug
discovery project when the reality of biological complexity
considered.4.2. What side eﬀects might a compound have?
Side eﬀects of candidate drugs are common, and can lead to
delays and failures at comparatively late stages in the discovery
process. Any eﬀects that can be predicted early are thus of
great advantage, and pathways can indeed sometimes help
do just this.
Some side eﬀects are caused by a drug binding to a similar
(i.e., homologous protein). A good example is the phospho-
diesterase (PDE) inhibitor Viagra (Sidenaﬁl). Originally de-
signed to target PDE-5 and promote the relaxation of
smooth muscle [26], the compound also binds to the homol-
ogous PDE-6 in the eye, which leads to a ‘‘blue vision’’ side
eﬀect in patients [27]. Such subtle ocular eﬀects are diﬃcult
to detect in animals, thus making eﬀorts to predict them
key. CCNets PathTox tool readily indexes a simple se-
quence search to our pathway collection and ﬁnds these
two enzymes and the likely eﬀects of blocking them (Fig.
Fig. 1. Pathways involving Cox-2. Biochemical Pathway of Cox-2 [25] (a) in the formation of prostanoids and the term connectivity (b) of Cox-2 as
represented by the pathway-mining tool PathwayAssist. Red symbols denote proteins, yellow physiological processes and green represent small
molecules.
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Fig. 2. Example of how drug-speciﬁcity problems might be predicted
using pathway information. The ﬁgure shows simpliﬁed parts of the
smooth-muscle relaxation pathway (left) and light-sensing pathway in
the eye (right). The molecular target for Viagra is PDE-5, a
phosphodiesterase in smooth muscle, which is homologous to PDE-6
in the eye (indicated by a broken red line), and to which Viagra
(Sidenaﬁl) also binds, leading to a well-documented side eﬀect of blue
vision in patients (e.g. [27]).
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made to design more selective compounds, and thus poten-
tially avoid problems because of this cross-reactivity.4.3. What is the molecular explanation for an observed toxicity?
Toxicology is currently a great bottleneck. Promising drug
candidates very often fail to reach the market owing to unpre-
dictable eﬀects unrelated to the mechanism of drug action (e.g.,
binding the wrong molecule). Moreover, the molecular basis of
toxic eﬀects observed during animal studies are frequently
poorly understood, or diﬃcult to transfer to humans. A sys-
tems context is clearly needed here [28], and it is here where
a pathway framework, when complemented with data from
other sources can be of great use.
For instance, if a toxicologist is interested in the possible
causes of a physiological observation such as ‘‘thyroid hyper-
plasia’’, it is desirable to identify candidate molecules and
pathways without resorting to days of intensive literature
investigation. Here, the pathway scaﬀold, when cross-refer-
enced to the literature can quickly provide clues. Protein or
gene ontologies, annotated features like functional domains
or binding sites, or the scientiﬁc literature (e.g., PubMed) are
of greater use when placed in a pathway context. Trends or
similarities can be sought that could give clues as to how path-
ways overlap or communicate with one another. These come
readily when an expert carefully studies the literature and adds
information as appropriate, though the process is hard to
automate. However, the process can be accelerated with vari-
ous text searching and mining tools (e.g., Natural Language
Processing, NLP) enhanced by biomedical and gene/protein
synonyms, or gene (GO) [29] or drug ontologies (e.g., http://
www.biowisdom.com). Given query biomedical terms (e.g.,
G. Apic et al. / FEBS Letters 579 (2005) 1872–1877 1875‘‘bile acids and toxicity’’) CCNet use the latest NLP technol-
ogy to retrieve relevant publications, considering not only pos-
sible synonyms and ontologies (syntax), but also applying
contextual ﬁlters (semantics) to remove irrelevant matches.
These are then cross-referenced to associated gene products,
and then to pathways to give the best possible molecular view
of a macromolecular observation (Fig. 3; www.cambridgecell-
networks.com/text).
A key issue in toxicology is to understand whether eﬀects ob-
served in tested animals (e.g., mice, dog) are transferable to hu-
mans. Careful discernment of orthologues (i.e., direct
equivalents of genes in diﬀerent species) from paralogues
(i.e., genes that may have duplicated since the species diverged)
is thus critical [30]. For instance, it is conceivable that one
might be able to dismiss a toxic eﬀect observed, say, in mouse
if one can argue that corresponding pathways are diﬀerent in
humans, thus rescuing a compound that might otherwise be
discarded.
4.4. How can toxic eﬀects be tracked indirectly?
Many toxic eﬀects are related to a candidate molecule bind-
ing to proteins other than the target which are involved in crit-
ical cell processes. Even when the mechanism is well
understood, the biochemistry or the location of the molecules
involved can make direct testing for the phenomenon diﬃcult.
A systems view, in particular pathway walking can often un-
cover an alternative, indirect test.
We have applied this approach in order to suggest alterna-
tive routes for testing whether candidate molecules interfere
with bile acid transport (a common toxic eﬀect). Bile acid
homeostasis in the liver is tightly controlled by a system
involving several nuclear hormone receptors (FXR, LXR,
PXR, etc.) [31,32]. Bile acids activate FXR, which in turn reg-
ulates the expression of enzymes involved their synthesis
(Cyp7A1 and Cyp8B1) [33,34], through a negative feedbackFig. 3. Integration of pathways, interactions and the literature to ﬁnd missin
extract meaningful abstracts and their associated molecules and interactions
missing links between pathways (blue line), and to provide explanations forloop. FXR also regulates the expression of several bile-acid
transport proteins including BSEP/SPGP [35]. A full picture
of this process can be obtained only through a combination
of metabolic and signaling pathways and the extraction of
genes regulated by FXR using text-mining (Fig. 4).
Assaying the biochemical activity of transporters directly is
extremely problematic. However, pathway-walking along the
gene regulatory network surrounding FXR suggests that trans-
porter activity would be tightly correlated with the expression
of other FXR regulated genes, and thus in principle one could
monitor transport function indirectly via expression analysis.5. Combination drugs: towards the design of magic shrapnel
Most of the discussion above, like much of modern drug dis-
covery, assumes that one is dealing with a single compound
with (in the best scenario) a single target. However, this rather
neglects both ancient and modern remedies that consist of two
or more compounds acting in concert.
Treatments containing more than one bioactive compound
are as old as medicine itself. Herbal remedies have long been
known to contain a great number of diﬀerent substances,
and it is often diﬃcult to discern what, if anything, each of
them is doing. There are some indications that herbal remedies
elicit their beneﬁcial eﬀects by tinkering with diﬀerent receptors
in pathways in a gentle way. Instead of a single, concentrated
magic bullet, they contain several compounds with lower con-
centrations more like magic shrapnel. It is even possible for
one compound to partly counteract another. For instance,
the nutracuetical ginseng has both wound healing and anti-
tumor eﬀects through opposing activities on vascular system
[36]. DNA microarrays and chemical ﬁngerprinting have re-
cently revealed that ginseng indeed contains two active sub-
stances with opposite eﬀects, Rg1 that leads to angionenesisg links. The ﬁgures shows how a text query can be used (via NLP) to
, and how these can be mapped onto pathways (gray lines) to suggest
the molecular mechanisms related to the query.
FXR
CYP7A1 BSEP/SPGPMRP2CYP8B1 SULT2A1IBABP
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-
Fig. 4. Regulation of genes by FXR in the presence of bile acid. The ﬁgure shows a part of the negative feedback loop in control of bile acid
homeostasis in liver. Enzymes involved in bile acid synthesis are shown in green and the other proteins in blue (farnesoid X receptor, FXR), organic
anion transport protein 2 (OATP2), DHEA–sulfate transferase (SULT2A1), peroxisome proliferator-activated receptor-alpha (PPARa), ileal bile
acid biding protein (IBABP), multidrug resistance protein 2 (MRP2), Sister of P-glycoprotein SPGP/bile salt export pump (BSEP/SPGP). Plus/minus
symbols (+/) denote increase/decrease in expression or activity through direct or indirect mechanisms. The elements of this pathway were extracted
using CCNets software.
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early angiogenesis pathway [36].
This natural precedent poses the obvious question for new
drugs: can we rationally design mixtures such as those discov-
ered in herbal medicine? Probably a deeper understanding of
pathways is ultimately needed, but certainly great hope comes
from the revolutionary approach of CombinatoRx. Rather
than attempting rational design based on a single drug target,
they performed a high-throughput screen of 120 000 pair-wise
combinations of 600 established drugs in various phenotypic
assays (from cellular assays to whole organisms such as zebra
ﬁsh) [37]. The hope was that side eﬀects typical of new drugs
could be avoided through the use of combinations of those
that have already passed successfully through toxicology,
safety and clinical trials. The results were astonishing: some
combinations had unpredictable beneﬁcial eﬀects that were
not related to those known for the individual substances.
For instance, the combination of the anti-psychotic chlor-
promazine and the anti-protozoal pentamidine, neither of
which show any anti-tumor activity, prevented the tumor
growth in mice [37]. No obvious mechanism was clear from
what was known about the two compounds: a new eﬀect
resulted from a delicate interplay between the pathways
involved.
Screens like these provide unprecedented insight into con-
nectivites of biological pathways. The challenge for experimen-
tal and computational systems biologists is to make sense of
such complex mixtures beyond what is already known about
their individual components.6. Concluding remarks
Scientists in pharmaceutical companies are continually
forced to make tough decisions related to which of several
compounds should be taken further when millions have al-
ready been spent on each of them. The decisions must often
be made without a detailed understanding of the mechanismof action. Better understanding of human disease biology will
clearly lead to faster and more accurate decisions. Biological
pathways, though still error-prone and far from complete in
coverage, can now provide a more eﬃcient way of browsing
through pharmaceutically relevant information, and oﬀer a
quick overview of underlying molecular processes. These and
other eﬀorts in systems biology are already progressing to-
wards a systematic understanding of the molecular mecha-
nisms of disease biology and drug action.
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